|
Getting your Trinity Audio player ready...
|
Pfizer released another round of data from its vaccine trials last Friday. Pfizer is doing this begrudgingly after a court in Texas ordered them to do this. Originally they pledged to release this in 75 years.
So what does the latest round of research say?
First, the company un-redacted the total number of vaccines shipped between December 1, 2020 and February 28, 2021. That number is 126,212,580. We had known that there were 42,086 adverse vaccine effects but we couldn’t work out a percentage due to the unpublished sample size. Now we know that this works out to 0.0003% of cases.
That’s nice, but further on in the report, the data seems to suggest that the unvaccinated faired better after a Covid diagnosis than the vaccinated. See Table 5 of this document showing that vaccinated people were more likely to catch and be hospitalized for Covid than those who were fully vaccinated. This also seems to debunk the common refrain of those (like us) who had breakthrough cases and thought that “it could have been much worse without having had the vaccine.” The data does not conclude that yet.
In fact, the CDC has confirmed this data too showing that those who had Covid naturally had just as much, if not more protection from Covid than those who had the vaccine.
The Pfizer documents go on to say that not all adverse cases were “fully processed” due to staffing shortages.
“Pfizer has also taken a multiple actions to help alleviate the large increase of adverse event reports… To date, Pfizer has onboarded approximately 600 additional full- time employees (FTEs). More are joining each month with an expected total of more than 1,800 additional resources by the end of June 2021.” (Page 6)
That’s not comforting. Why don’t we similar data from Moderna’s vaccine? Because Moderna is still administering its vaccine with “emergency approval.” Some could argue that many countries are out of the emergency phase so why won’t the company complete the FDA process and show us what they’ve got?
These are troubling questions, we know. It is worth noting that Pfizer did better than expected in recent earnings and the stock is expected to skyrocket further with the rollout of the Covid treatment pill.
